drugset / Trial / NCT00911287

Oxymorphone Extended Release (ER) in Opioid-Naive Patients With Chronic Pain

NCT00911287

Phase 3 Completed 129 enrolled Endo USA Inc., a Keenova Therapeutics Company
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if oxymorphone ER is effective and safe in treating chronic pain in opioid-naive patients.

Timeline

Start
2003-06
Primary completion
2004-01
Completion
2004-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxymorphone Small molecule 5 mg
Subject Oxymorphone Small molecule 10 mg
Subject Oxymorphone Small molecule 20 mg

Indications